Severe traumatic brain injury (sTBI) is often accompanied by coagulopathy and an increased risk of bleeding. To identify and successfully treat bleeding disorders associated with sTBI, rapid assessment of coagulation status is crucial. This retrospective study was designed to assess the potential role of whole-blood thromboelastometry (ROTEM Ò , Tem International, Munich, Germany) in patients with isolated sTBI (abbreviated injury scale [AIS] head ‡ 3 and AIS extracranial < 3). Blood samples were obtained immediately following admission to the emergency room of the Trauma Centre Salzburg in Austria. ROTEM analysis (EXTEM, INTEM, and FIBTEM tests) and standard laboratory coagulation tests (prothrombin time index [PTI, percentage of normal prothrombin time], activated partial thromboplastin time [aPTT], fibrinogen concentration, and platelet count) were compared between survivors and non-survivors. Out of 88 patients with sTBI enrolled in the study, 66 survived and 22 died. PTI, fibrinogen, and platelet count were significantly higher in survivors ( p < 0.005). Accordingly, aPTT was shorter in this group ( p < 0.0001). ROTEM analysis revealed shorter clotting times in extrinsically activated thromboelastometric test (EXTEM) and intrinsically activated thromboelastometric test (INTEM) ( p < 0.001), shorter clot formation times in EXTEM and INTEM ( p < 0.0001), and higher maximum clot firmness in EXTEM, INTEM, and FIBTEM ( p < 0.01) in survivors compared with non-survivors. Logistic regression analysis revealed extrinsically activated thromboelastometric test with cytochalasin D (FIBTEM) MCF and aPTT to have the best predictive value for mortality. According to the degree of coagulopathy, non-survivors received more RBC ( p = 0.016), fibrinogen concentrate ( p = 0.01), and prothrombin complex concentrate ( p < 0.001) within 24 h of arrival in the emergency room. ROTEM testing appeared to offer an early signal of severe life-threatening sTBI. Further studies are warranted to confirm these results and to investigate the role of ROTEM in guiding coagulation therapy.
Introduction

S
evere traumatic brain injury (sTBI) accounts for 60% of injury-related mortality and is the leading cause of death following trauma (Shackford et al., 1993) . Strongly associated with increased morbidity and mortality, coagulopathy in sTBI is a frequent problem (Lustenberger et al., 2010a; Talving et al., 2009; Wafaisade et al., 2010) . Reports on the incidence of coagulopathy in sTBI are rare and they are usually not comparable due to variations in inclusion criteria for the study population, definitions of coagulopathy, and time points of coagulation analysis following hospital admission (Lustenberger et al., 2010a; Selladurai et al., 1997; Wafaisade et al., 2010; Zehtabchi et al., 2008) .
Presently, the optimum coagulation test threshold values on which to base treatment decisions in patients with sTBI are not defined. Standard coagulation tests such as prothrombin time (PT), prothrombin time index (PTI, PT as a percentage of normal) or the International Normalized Ratio (INR), activated partial thromboplastin time (aPTT), plasma fibrinogen concentration, and platelet count cannot provide insight into the complexity of coagulopathy, but most trauma centers continue to rely on them (Kuo et al., 2004; Selladurai et al., 1997; Wafaisade et al., 2010; Zehtabchi et al., 2008) . It should be noted that these tests were not developed to assess coagulopathy in acute bleeding, nor have they been validated for predicting bleeding (Dzik, 2004; Kitchens, 2005) .
Recently the potential value of viscoelastic tests (thromboelastometry [ROTEM] or thromboelastography [TEG] ) for coagulation assessment in various clinical scenarios has been recognized (Huissoud et al., 2009; Johansson et al., 2009; Kashuk et al., 2009; Rahe-Meyer et al., 2009a; Schö chl et al., 2009) . A key advantage of ROTEM/TEG over standard coagulation tests is that they provide information not only on the initiation phase of clot formation, but also on the kinetics of clot growth, final clot strength, and, if occurring, fibrinolytic breakdown of the clot. Thus, these established point-of-care technologies allow a differentiated approach to blood coagulation management (Schö chl et al., 2010b) . Viscoelastic testing is increasingly being used to guide coagulation therapy, tailored to each patient's specific requirements ( Johansson et al., 2010; Kashuk et al., 2010a; Rahe-Meyer et al., 2009b; Schö chl et al., 2010a) .
There are no published data on the use of ROTEM/TEG to monitor coagulopathy in sTBI patients. We assessed the coagulation status of survivors and non-survivors of isolated sTBI immediately after arrival at the emergency room (ER), with the aim of comparing point-of-care ROTEM data with standard coagulation tests. We hypothesized that coagulopathy is indicative of outcome in sTBI patients and that it can be identified with both standard laboratory coagulation tests and point-of-care ROTEM tests.
Methods
After approval from the Ethics Committee of the State of Salzburg, we retrospectively analyzed data from patients admitted to the Trauma Centre Salzburg in Austria, between January 2005 and October 2010. The inclusion criterion for the study was isolated sTBI, defined by an Abbreviated Injury Scale for head (AIS head ) ‡ 3 and an AIS for extracranial injuries (AIS extracranial ) < 3, where 3 is rated as ''serious.'' There are no previous data on this type of coagulation testing in brain injury patients; therefore, sample size could not be calculated formally. However, assuming a non-survivor -survivor ratio of 1:3, a between-group difference of 0.7 times the standard deviation would be detectable if 80 cases were included (a = 0.05, power 0.80).
Demographic data, blood pressure, and Glasgow Coma Scale (GCS) score upon admission to ER were collected from the anesthesia charts. In patients receiving rapid sequence intubation (RSI) in the field, GCS score was obtained from the report of the emergency physician in charge. ROTEM measurements (EXTEM or INTEM, and FIBTEM) were reviewed from the database, which stores data from the device. Standard coagulation test results were obtained from the laboratory data management system. Finally, we collected information on patient survival after trauma.
Since 2001, thromboelastometry (ROTEM Ò , Tem International, Munich, Germany) has been integral to our coagulation monitoring and treatment protocol for all major trauma cases requiring full trauma team activation in the ER. ROTEM analyses were performed at the bedside by the attending anesthetist or intensivist (at the Trauma Centre Salzburg, standard procedure is for an anesthetist and an intensivist to attend all ER admissions). Blood samples for ROTEM analysis and standard coagulation tests were collected in 3 mL tubes containing 0.3 mL buffered 3.2% trisodium citrate, giving a volume ratio of 1:9. Point-of-care ROTEM analyses were performed within minutes of sample collection in the ER. Three ROTEM analyses were performed routinely: an extrinsically activated assay with recombinant tissue factor (EXTEM), an intrinsically activated test using kaolin (INTEM), and an extrinsically activated test with recombinant tissue factor and addition of cytochalasin D (FIBTEM). Cytochalasin D inhibits platelet function by blocking changes in the platelet cytoskeleton; therefore, this test provides information on the fibrin-based component of the clot. An additional aprotinin-based test (APTEM) was performed in most cases to detect hyperfibrinolysis (Schö chl et al., 2009 Ò S Blood Gas Analyzer [Roche Diagnostics]; normal range for BE, -3.0 to + 3.0 mmol/L; normal range for lactate, 0.5-2.2 mmol/L). Fibrinogen concentration was measured by the Clauss method (optical read-out), using a fully automated blood coagulation analyzer (Sysmex Corporation, Kobe, Japan; normal range, 175-400 mg/dL). Hemoglobin, hematocrit, and platelet count were analyzed using blood samples anticoagulated with ethylenediamine tetra-acetic acid, with an SF 3000 analyzer (Sysmex).
Definition of coagulopathy
Using standard coagulation tests, coagulopathy was defined as one or more of the following results: PTI < 70%, aPTT > 35 sec, fibrinogen <150 mg/dL, and platelet count <100,000/lL. The PTI threshold was chosen based on the work of Wafaisade and colleagues (2010) . The aPTT threshold used was the upper limit of normal in our laboratory, and the fibrinogen concentration threshold was based on the recommendation of the European guidelines for bleeding management of trauma patients (Rossaint et al., 2010) . Using ROTEM results, coagulopathy was defined according to Lang and associates as one or more of the following results: EXTEM CT > 80 sec, EXTEM CFT > 159 sec, EXTEM MCF < 50 mm, INTEM CT > 240 sec, INTEM CFT > 110 sec, INTEM MCF < 50 mm, and FIBTEM MCF < 9 mm (Lang et al., 2005) .
Statistical analysis
Demographic and clinical data were presented as mean -standard deviation or median and range (minimum,
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SCHÖ CHL ET AL. Stepwise logistic regression was used to identify the best predictor of mortality/survival. ER systolic blood pressure and heart rate, hemoglobin, platelet count, PTI, aPTT, fibrinogen concentration, and ROTEM variables were included, and all parameters from the bivariate analysis with a p value of < 0.2 were used. As a measure of discrimination not dependent on a certain cut-off point, the area under the receiver operating characteristic (ROC) curve was determined, together with its 95% confidence interval (CI). A p value of < 0.05 was considered significant for all statistical tests.
The statistical calculations were performed using GraphPad Prism 5.03 (GraphPad Software, La Jolla, CA) and IBM SPSS 19 (SPSS Inc., Chicago, IL).
Results
During the 69-month study period, 273 patients with the diagnosis of traumatic brain injury were identified from our intensive care unit database. Of these, 88 suffered from sTBI and met the inclusion criteria. Seventy-six percent of patients included in the study were males, and the median age was 47 years (IQR, . Demographic data, GCS score at the accident site, and clinical data on arrival at the ER are outlined in Table 1 . RSI was performed on 77% of patients by emergency physicians in the field. Twenty-two of the patients (25%) died, mostly from uncontrolled intracranial pressure, with a median time to death of 2 days (IQR, 0-10). No significant differences were observed in pre-hospital fluid therapy between survivors and non-survivors.
Blood cell count, standard coagulation tests, and blood gas analysis for survivors and non-survivors on admission to the ER are listed in Table 2 . PTI was significantly higher and aPTT was significantly shorter in survivors vs. nonsurvivors ( p < 0.0001 for both; Fig. 1) . Fibrinogen values were significantly lower in non-survivors ( p < 0.0001; Fig. 1 ). Platelet count was also significantly lower in non-survivors ( p = 0.004), although only one patient in the non-survivor group and none in the survivor group had a platelet count < 100,000/lL. No significant differences were detected for pH, BE, and lactate.
Significant differences in ROTEM variables upon arrival at the ER were observed between survivors and non-survivors. Survivors had significantly shorter CT in EXTEM ( p < 0.001) and INTEM ( p < 0.001; Fig. 1 ). Similarly, in the EXTEM test, CFT was 106 sec (83-129) in survivors vs. 154 sec (120.8-304) in non-survivors ( p < 0.0001), while in the INTEM test, CFT was 84 sec (69-110) in survivors, and 116 sec (90-229) in nonsurvivors ( p < 0.0001; Fig. 2 ). The amplitude of clot firmness at 5-min intervals (A5-A30) and MCF for EXTEM, INTEM, and FIBTEM analyses were all significantly lower in nonsurvivors than in survivors ( p < 0.01; Fig. 3 ). LI60 and ML did not differ significantly between the groups. ROTEM measurements in the ER showed that three patients suffered from hyperfibrinolysis; these three patients died. Standard test results and ROTEM analyses outside normal range in survivors and non-survivors are shown in Table 3 .
PTI and EXTEM CT data were available for 82 patients. As stated in the Methods section, coagulopathy was defined by PTI < 70% and EXTEM CT > 80 sec. Using these criteria, 47 of the 82 patients (57.3%) had normal coagulation according to both PTI and EXTEM CT, while 13 patients (15.8%) had coagulopathy according to both tests. Normal EXTEM CT but impaired PTI was observed in 11 patients (13.4%), while the same number of patients (13.4%) had prolonged EXTEM CT but normal PTI. The result of the chi-square test for the diagnosis of coagulopathy (PTI < 70% and EXTEM CT > 80 sec) was significant ( p = 0.003), indicating broad agreement between the two parameters in classifying patients as coagulopathic. Hemostatic therapy and transfusion requirements of survivors and non-survivors are outlined in Tables 4 and 5. As expected, non-survivors received significantly more RBCs, fibrinogen concentrate, and PCC (Table 4) . However, when comparing the patients in both groups who received coagulation therapy, no between-group differences were observed in the amounts of each product administered, except for fibrinogen concentrate therapy during the first 6 h (Table 5 ; p = 0.009). Table 6 shows the results of the stepwise logistic regression analyses. Coagulation tests independently associated with mortality were FIBTEM MCF and aPTT. The area under the ROC curve for identifying was 0.77 (95% CI, 0.665-0.850; p < 0.001) for FIBTEM MCF and 0.79 (95% CI, 0.686-0.868; p < 0.001) for aPTT (Fig. 3) .
Discussion
This is the first study reporting ROTEM findings in a cohort of patients with sTBI. ROTEM analysis revealed significant differences between survivors and non-survivors immediately 
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upon arrival at the ER. ROTEM results are readily available in the ER. In this study they provided a comprehensive analysis of the coagulation status, as confirmed by standard laboratory results, which became available later in the course of patient care. Standard coagulation tests (PT, PTI, aPTT, fibrinogen plasma concentration, and platelet count) are widely used to assess coagulopathy in patients with sTBI (Selladurai et al., 1997; Wafaisade et al., 2010) . However, there are some limitations with regard to their usefulness and applicability in acute bleeding situations. Firstly, they are usually time consuming and, even under ideal logistical circumstances, the results will not be available in < 20-30 min. A French study revealed median turnaround times of 88 min (range, 29-235 min) when blood collection tubes were sent to the central laboratory (Toulon et al., 1998) . Secondly, standard coagulation tests are completed upon formation of the first fibrin strands, when only approximately 5% of thrombin has been generated. Accordingly, they provide information only on the initiation of clot formation (Mann et al., 2003) . In contrast, viscoelastic tests assess the patient's coagulation status within minutes (Luddington, 2005) . They also offer information on clot firmness and clot stability, as well as the initiation of coagulation.
It has been shown that coagulopathy following sTBI is strongly related to poor outcome (Cohen et al., 2007; Kerney et al., 1992; Olson et al., 1989; Stein and Smith, 2004; Talving et al., 2009; Wafaisade et al., 2010) . In previous studies, a correlation was observed between the extent of damaged brain tissue and the degree of coagulopathy (Goodnight et al., 1974; Kerney et al., 1992) . Brain tissue contains high concentrations of thromboplastin, and because this protein acts as a procoagulant when released into the bloodstream, the risk of disseminated intravascular coagulation is increased in patients with sTBI (Scherer and Spangenberg, 1998) . Furthermore, coagulation factors and platelets are activated by damaged cerebral endothelium, resulting in microthrombosis and further depletion of coagulation factors (Kerney et al., 1992; Olson et al., 1989) . Cohen and colleagues (2007) suggested hypoperfusion and shock as the major drivers of coagulopathy in patients sustaining sTBI. However, this hypothesis was challenged recently by Lustenberger and colleagues (2010b) who reported that hypoperfusion is an independent risk factor for coagulopathy after sTBI, but that coagulopathy does not occur exclusively in patients sustaining major shock and tissue hypoperfusion.
Our study revealed that initiation of coagulation, described by CT in EXTEM and INTEM as well as PTI and aPTT, was significantly different between survivors and non-survivors. The prolongation of these tests (or a decreased value in the case of PTI) indicates delayed onset of coagulation, which may potentially contribute to the coagulopathy associated with sTBI. More severe impairment of coagulation among non-survivors could potentially be related to increased bleeding before admission among these patients (platelet count and levels of hemoglobin and fibrinogen all suggested more pronounced bleeding among non-survivors). However, data on pre-admission blood loss were not available for our patient cohort. Interestingly, 
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pre-hospital fluid therapy was not significantly different between survivors and non-survivors. At all time points, even after as little as 5 min (A5), clot firmness was significantly lower in non-survivors than in survivors. MCF in EXTEM and INTEM mimic the interaction of fibrin, platelets, and activated Factor XIII (Luddington, 2005) . It has been observed that platelet count is in the normal range in most sTBI patients on arrival at the ER (Carrick et al., 2005) . This was also true in our study population, with platelet count on admission to the ER > 100,000/lL in all but one patient. Therefore, the cause of significant reduction in EXTEM and INTEM MCF in non-survivors is unlikely due to decreased contribution of platelets to clot firmness, and more likely due to impaired fibrin formation. This is supported by the finding that both FIBTEM MCF and fibrinogen concentration were significantly lower in non-survivors compared to survivors.
It has been reported that defibrination in the course of sTBI is strongly associated with poor outcome (Kushimoto et al., 2003; Olson et al., 1989) . Goodnight and colleagues (1974) described major defibrination in 9 out of 13 patients with substantial brain tissue destruction, compared with 0 out of 13 in whom trauma did not apparently destroy brain tissue. This finding is in accordance with observations in the present study. Non-survivors had significantly lower FIBTEM MCF and fibrinogen levels upon admission compared to that of survivors. Increased consumption of coagulation factors, a characteristic of disseminated intravascular coagulation, could have contributed to the low fibrinogen levels in nonsurvivors (and also in some survivors). Interestingly, no significant difference was observed between survivors and non-survivors in the amount of fibrinogen concentrate administered to those patients who received coagulation therapy, except during the first 6-h period. Kushimoto and colleagues (2003) also suggested that hyperfibrinolysis is an important contributor to poor outcome in patients suffering from closed head injury. In the present study, hyperfibrinolysis was observed only in the non-survivors' group, in a total of three patients (14% of the non-survivors). This is in accordance with previous reports of hyperfibrinolysis being associated with high mortality (Kashuk et al., 2010b; Schö chl et al., 2009) . ROTEM/TEG is currently assumed to be the gold standard for detection of hyperfibrinolysis (Luddington, 2006) . It allows diagnosis of the hyperfibrinolytic state within a short time period (Schö chl, 2009 ). This important information is not provided by any other standard coagulation test. Recently, a major study presented evidence supporting the use of tranexamic acid in bleeding trauma patients (Shakur et al., 2010) . However, hyperfibrinolysis was infrequent in our cohort of patients, and we do not recommend routine use of tranexamic acid due to its potential to induce seizures (Furthmü ller et al., 2004) .
Limitations
Although hypothermia, acidosis, and fluid therapy may affect the results of standard coagulation tests and ROTEM analyses, there was no statistical correction for their potential effect in the present study. However, neither fluid therapy nor acidosis was significantly different between groups. The definition of coagulopathy varies between clinical scenarios. Our definitions of coagulopathy, using either standard coagulation tests or ROTEM test results, were based on values outside the normal range. However, due to the retrospective nature of our study, we did not investigate clinical signs of bleeding for comparison with the diagnosis of coagulopathy. Therefore, it is possible that some of the patients met the study criteria for coagulopathy but were not bleeding, or vice versa. Disseminated intravascular coagulation can cause coagulopathy in sTBI patients, but the design of this study did not permit diagnosis of this condition. The design of the study also did not provide scope for investigating how ROTEM parameters might be used to guide haemostatic therapy and potentially affect outcome. Fresh frozen plasma and desmopressin were not used; activated recombinant FVII (1), platelet concentrates (1), and tranexamic acid (3) were used in individual cases and are not included above.
Data are presented as mean -standard deviation, or median and interquartile range, according to the underlying distribution.
Conclusion
ROTEM provides rapid and useful information on the coagulation status of patients with isolated sTBI. Significant differences in ROTEM test results were observed between survivors and non-survivors. Delayed initiation of coagulation, increased CFT, and diminished clot strength were evident within minutes of patients' arrival at the ER. As defibrination is common in sTBI, early detection of this phenomenon is essential for guiding coagulation therapy. FIBTEM MCF can show diminished fibrin polymerization within minutes, and this may be considered the most useful ROTEM parameter. Prospective studies are warranted to provide further evidence of the usefulness of ROTEM in sTBI patients, as a basis for optimizing coagulation therapy among these patients.
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Risk factors entered into the model ( p < 0.2): aPTT > 35 sec, base excess < -6, EXTEM CT > 80 sec, EXTEM CFT > 130 sec, INTEM CT < 240 sec, INTEM CFT > 190 sec, FIBEM MCF < 9 mm, fibrinogen < 150 mg/ dL, hemoglobin < 11 g/dL, prothrombin time index < 70%.
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